Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Different techniques and devices can achieve haemostasis after endovascular procedures to reduce time to haemostasis and facilitate percutaneous large-bore access. One such device is the Angio-Seal, which accomplishes haemostasis by compressing a collagen plug against the arteriotomy. Multiple complications related to Angio-Seal exist, most commonly acute artery occlusions and rarely infections and endarteritis. We present a case of an adult male (aged 80–85) who developed a groin haematoma associated with Angio-Seal use. Arterial bypass for arterial reconstruction and intravenous antibiotics were required. This case addresses the associated pathologies of Angio-Seal failure and Angio-Seal infection, patient- and device-specific risk factors and measures to treat and prevent these complications (ANGIO-SEAL VIP Vascular Closure Device—6 Fr Terumo Medical, NJ, USA).
Different techniques and devices can achieve haemostasis after endovascular procedures to reduce time to haemostasis and facilitate percutaneous large-bore access. One such device is the Angio-Seal, which accomplishes haemostasis by compressing a collagen plug against the arteriotomy. Multiple complications related to Angio-Seal exist, most commonly acute artery occlusions and rarely infections and endarteritis. We present a case of an adult male (aged 80–85) who developed a groin haematoma associated with Angio-Seal use. Arterial bypass for arterial reconstruction and intravenous antibiotics were required. This case addresses the associated pathologies of Angio-Seal failure and Angio-Seal infection, patient- and device-specific risk factors and measures to treat and prevent these complications (ANGIO-SEAL VIP Vascular Closure Device—6 Fr Terumo Medical, NJ, USA).
DESCRIPTIONIn December 2011, an 83-year-old thin woman was referred to our emergency department because of 'a thoracic cutaneous abnormality'. In 2001, a permanent pacemaker had been implanted due to symptomatic sick sinus syndrome. Since then, she had remained well. Thirteen days before admission, a routine control assessment performed at pacemaker clinic displayed clinical and electrical normal fi ndings. On admission, physical examination was remarkable for the presence of two lesions in the skin lied just above the generator ( fi gure 1 ). The fi rst was ulceration with slight perilesional erythema and the second consisted on isolated erosion which let us directly see the generator. White cell blood count and erythrocyte sedimentation rate were within normal limits and blood cultures were negative. Complete device removal, pocket cleaning and closure, and reimplantation of a new pacemaker on the left-sided subpectoral region were carried out. As there were signs of pocket infection only, she was on antibiotic therapy for 14 days. Outcome was favourable. With an increasing number of indications for implantation of cardiac devices and considering that incidence rates of cardiac device infections usually range from 0.13% to 19.9% for permanent pacemaker, 1 clinicians can have the possibility to deal with this kind of condition in their common practice. Although ulceration of foreign bodies is not unusual, pacemaker infection presented as skin ulceration and erosion seems to be a rare event. 1 2 The pathogenesis of these disorders may include local infection and continuous pressure of the hard device against the overlying subcutaneous and cutaneous structures, 1 2 with ensuing development of tissue ischaemia and necrosis (like occur in other pressure ulcer cases). 3 Besides subsequent infectious complications, device erosion can result in loss of pacing. 4 Cure of cardiac device infections is possible in most patients with an approach that involves device extraction and antimicrobial therapy. 1,2 4Competing interests None. Patient consent
Purpose To assess the safety and efficacy of the StarClose SE Vascular Closure System (Abbott Vascular, Abbott Park IL, USA) in high-risk thrombocytopenic and coagulopathic interventional oncology (IO) patients. Methods In this single institution retrospective study, 63 high-risk thrombocytopenic or coagulopathic IO patients (M:F=51:12, mean age 58 years, range 31–88 years) who underwent 83 common femoral arteriotomy closures using the StarClose device were identified among all IO patients (n=131) undergoing StarClose closure (n=177) between 2008–2011. High-risk thrombocytopenia and coagulopathy were defined as platelet count ≤100 103/mL and international normalized ratio (INR) ≥1.5. Procedures included chemoembolization (n=67), radioembolization (n=8), and hepatic arterial mapping with technetium-99m macroaggrated albumin administration (n=8) for treatment of hepatocellular carcinoma (n=79) or liver metastases (n=4). Measured outcomes included technical success of arterial closure and closure-related adverse events, graded according to the Society of Interventional Radiology classification. Results In all cases, 5 French common femoral arterial access was used. Platelet count was ≤100 103/mL in 80/83 (96.4%) cases and INR was ≥1.5 in 35/83 (42.2%) cases. Mean pre-procedure platelet count was 71 (range 26–347) 103/mL and mean INR was 1.4 (range 1.0–2.1). The StarClose device effectively sealed the arteriotomy in 83/83 (100%) cases, 60/83 (72.3%) cases were first-time closures, and 20/83 (24.1%) cases were repeat closures. Small groin hematomas, graded as class A minor complications, developed in 3/83 (3.6%) cases. No other complications were encountered. Conclusions The StarClose SE Vascular Closure System confers high technical success and safety in common femoral arteriotomy closure in high-risk IO patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.